MC
ITCI

Maverick Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Maverick Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,005
Closed -$251K – 302
2024
Q4 		$251K Buy
+3,005
New +$247K ﹤0.01% 208
2024
Q2 		– Sell
-3,660
Closed -$253K – 489
2024
Q1 		$253K Buy
+3,660
New +$252K ﹤0.01% 375
2023
Q2 		– Sell
-9,057
Closed -$490K – 567
2023
Q1 		$490K Buy
+9,057
New +$438K 0.01% 271
2021
Q3 		– Sell
-9,462
Closed -$386K – 831
2021
Q2 		$386K Buy
+9,462
New +$350K ﹤0.01% 416

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Maverick Capital's ITCI Position: Q1 2025 in Review

Maverick Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 3,005 shares — an estimated $251K sold.

Maverick Capital first reported a position in ITCI in Q2 2021 and held it in 4 quarters. The position peaked at $490K in Q1 2023. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Maverick Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Maverick Capital sold 3,005 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $251K.
  • Maverick Capital first reported a position in Intra-Cellular Therapies Inc. in Q2 2021 and held it in 4 quarters.
  • Maverick Capital's Intra-Cellular Therapies Inc. position peaked at $490K in Q1 2023.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Maverick Capital's 13F filing for Q1 2025, filed 15 May 2025.